ETF and index data management specialists
  • Why Ultumus
  • Our Products
    • Global Index Aggregation
    • Global ETF Aggregation
    • PCF Calculation
    • Global Dividend Forecast
  • News & Insights
  • Contact Us

News , GERM , ETFMG

Covid Vaccines

By Bernie Thurston
June 19, 2020

USA

Another coronavirus ETF

ETF Managers Group has come in first in the race to roll out a coronavirus ETF, with the ETFMG Treatments Testing and Advancements ETF (GERM) commencing trading this week. 

The invests mostly in healthcare biotech companies. It aims to invest in those that develop vaccines, and in those that produce tests for vaccines. Companies are identified based on revenue purity and stages of drug development. 

Like a lot of thematic funds, the fund uses funky wedding-cake style weighting system. The weighting system is designed to give medium-sized companies a bigger footprint. It allows companies with market caps under $15 billion to take up to 6% of the index. 

Large caps, i.e. those with market caps $15B-plus, get equally weighted with their collective weights not allowed to take more than 10% of the index. 

The fund charges of 0.68%.

Quite possibly the ticker for 2020

Subscribe to our Blog Notifications

All posts
About Author
Bernie Thurston

You might also like
MSCI Reclassification of Lebanon from Frontier Markets to Standalone
MSCI Reclassification of Lebanon from Frontier Markets to Standalone
June 19, 2020
MSCI Reclassification of Iceland from Standalone to Frontier Markets
MSCI Reclassification of Iceland from Standalone to Frontier Markets
June 19, 2020
Fighting Fat ETF
Fighting Fat ETF
June 19, 2020
Ultumus Logo

Our market leading technology powers four highly customizable solutions.

Products
  • Index Aggregation
  • ETF Aggregation
  • PCF Calculation
  • Dividend Forecast
Site map
  • Why Ultumus
  • Our Products
  • Insights
  • Contact Us
Contact Us
  • +44 (0) 203 998 2500
  • info@ultumus.com

©2021. All rights reserved